Other substances

FX06

A fibrin-derived peptide.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
1
 Clinical trials

General information

FX06 is a peptide derived from fibrin. It inhibits the migration of leukocytes across the gap junctions in endothelial cells (DrugBank).

Synonyms

Fibrin-derived peptide Bβ15-42

 

MKHLLLLLLCVFLVKSQGVNDNEEGFFS

Supporting references

Link Tested on Impact factor Notes Publication date
Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome
ARDS Peptide Critical severity Case series 		Patients 2.69

Observed increase in mean oxygenation and decrease in serum IL-6. Sample size: 6. Dosage: 400–600 mg per day; 3–7 days.

 Sep/24/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04618042 FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia Completed Phase 2 Nov/13/2020 Jun/13/2021
  • Alternative id - APHP200495|2020-002056-20
  • Interventions - Drug: FX06|Drug: Placebo of FX06
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Service de Médecine Intensive Réanimation - CHU Angers, Angers, France|Service de Médecine Intensive Réanimation - CHI de Poissy, Chambourcy, France|Hôpital Pitié Salpêtrière, Paris, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in extravascular lung water index (EVLWi)|Evolution of daily extravascular lung water index (EVLWi)|Evolution of daily cardiac index|Evolution of global end-diastolic volume index|Evolution of pulmonary vascular permeability index|Overall survival|Mortality rate in ICU and in hospital|Rate of withdraw or withhold life-sustaining treatments decision|Daily weight|Daily fluid balance|Evolution of albuminemia|Duration of mechanical ventilation|Proportion of participants alive and off invasive mechanical ventilation|Evolution of Murray ARDS severity score|Evolution of radiological Weinberg score|Evolution of pulmonary Sequential Organ Failure Assessment) score.|Rate of rescue therapy with Veino-veinous V-ECMO|Evolution of SOFA (Sequential Organ Failure Assessment) score|Organ failure free days|Renal replacement therapy free days|Duration of renal replacement therapy free days|Nature and frequency of adverse events|Evolution of FX06 concentration|Immunogenicity (antibody against FX06) induced by the drug, performed by ELISA according to manufacturer's procedure
Export (.csv)